The universal non-neuronal nature of parkinson's disease: a theory by Valente, André et al.
The universal non-neuronal nature of Parkinson's disease: A
theory
Various recent developments of relevance to Parkinson's disease (PD) are discussed and
integrated into a comprehensive hypothesis on the nature, origin and inter-cellular mode
of propagation of late-onset sporadic PD. We propose to define sporadic PD as a
characteristic pathological deviation in the global gene expression program of a cell: the
PD expression-state, or PD-state for short. Although a universal cell-generic state, the PD-
state deviation would be particularly damaging in a neuronal context, ultimately leading to
neuron death and the ensuing observed clinical signs. We review why age accumulated
damage caused by oxidative stress in mitochondria could be the trigger for a primordial
cell to shift to the PD-state. We put forward hematopoietic cells could be the first to
acquire the PD-state, at hematopoiesis, from the disruption in reactive oxygen species
(ROS) homeostasis that arises with age in the hematopoietic stem-cell niche. We argue
why, nonetheless, such a process is unlikely to explain the shift to the PD-state of all the
subsequently affected cells in a patient, thus indicating the existence of a distinct
mechanism of propagation of the PD-state. We highlight recent findings on the intercellular
exchange of mitochondrial DNA and the ability of mitochondrial DNA to modulate the
cellular global gene expression state and propose this could form the basis for the
intercellular propagation of the PD-state.
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ABSTRACT 
     Various recent developments of relevance to Parkinson's disease (PD) are discussed and 
integrated into a comprehensive hypothesis on the nature, origin and inter-cellular mode of 
propagation of late-onset sporadic PD. We propose to define sporadic PD as a characteristic 
pathological deviation in the global gene expression program of a cell: the PD expression-state, or 
PD-state for short. Although a universal cell-generic state, the PD-state deviation would be 
particularly damaging in a neuronal context, ultimately leading to neuron death and the ensuing 
observed clinical signs. We review why age accumulated damage caused by oxidative stress in 
mitochondria could be the trigger for a primordial cell to shift to the PD-state. We put forward 
hematopoietic cells could be the first to acquire the PD-state, at hematopoiesis, from the 
disruption in reactive oxygen species (ROS) homeostasis that arises with age in the hematopoietic 
stem-cell niche. We argue why, nonetheless, such a process is unlikely to explain the shift to the 
PD-state of all the subsequently affected cells in a patient, thus indicating the existence of a 
distinct mechanism of propagation of the PD-state. We highlight recent findings on the 
intercellular exchange of mitochondrial DNA and the ability of mitochondrial DNA to modulate the 
cellular global gene expression state and propose this could form the basis for the intercellular 
propagation of the PD-state. 
 
INTRODUCTION 
     Parkinson's Disease (PD) is as a movement disorder clinically characterized by tremor, 
bradykinesia, rigidity and postural instability [1]. The motor dysfunctions are a direct consequence 
of the death of dopamine-producing neurons in the substantia nigra pars compacta region of the 
midbrain. Histologically, the most noticeable feature of PD are abnormal aggregates of proteins, 
called Lewy bodies and Lewy neurites, that appear in the cell body and neurites of PD patient 
neurons. Their major constituent is the protein alpha-synuclein. 
     Familial genetic linkage studies have unequivocally associated six genes with Mendelian 
inheritable forms of PD [1]. Still, these individual gene mutations account for fewer than 10% of PD 
cases. They lead generally to juvenile or early onset PD (before age 50). 
     Naturally, genetics still impacts the chance of an individual acquiring non-monogenic sporadic 
PD later in life. Over a dozen single nucleotide polymorphisms (SNPs) have been statistically linked 
with sporadic PD through genome-wide association studies (GWASs) [2,3]. However, the 
differential risks associated with carrying these SNPs, although statistically significant, are mostly 
very small in absolute terms. Similarly, although some environmental factors, such as exposure to 
metals or pesticides, have  been statistically linked with PD, the associations do not appear to be 
sufficiently widespread to explain beyond a minority of PD cases [4]. Thus, the etiology of the over 
90% of cases classified as sporadic late-onset PD remains undetermined. 
     We briefly highlight some of the major theories being pursued regarding the nature of sporadic 
PD. Different aspects of these hypotheses will be called upon and presented in more detail 
whenever relevant, throughout the article. An overarching hypothesis on sporadic PD is that it is 
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caused by an external agent. Pesticides and metals would be two candidate environmental agents, 
given their statistical association with PD alluded to above [4]. Another possibility would be a 
neurothropic pathogen, such as a virus [5] or a prion-like protein [6]. Entry into the organism could 
be via the peripheral olfactory system [7] or via the gastrointestinal tract [8], two sites associated 
with early prodromal clinical symptoms of PD. These two sites have also been combined into a 
dual-hit hypothesis, that proposes that the external agent simultaneously enters the organism via 
the two routes [9]. Whether with an initially external origin or endogenously generated, the 
theory that a misfolded, prion-like self-propagating form of alpha-synuclein is responsible for the 
disease is another major hypothesis currently under investigation [6,10]. More endogenous, aging-
related perspectives of sporadic PD are very centered on the role of oxidative stress and 
mitochondrial damage, for which there is significant evidence in PD patients [11,12]. Finally, 
although the view of sporadic PD as an autoimmune disease is not typical, the aggravating 
contribution of the neuro-inflammatory response to the disease is commonly acknowledged 
[13,14]. 
     In this article, we combine some recent developments of relevance to sporadic PD with a 
number of more established PD findings in a comprehensive hypothesis on the nature, origin and 
inter-cellular mode of propagation of sporadic PD. 
 
THE UNIVERSAL NATURE OF THE PD-STATE 
     The application of induced pluripotent stem cell (iPSC) technology to PD research is a recent 
development in the field. Using iPSC techniques, conveniently collected cells from PD patients, 
such as skin fibroblasts, can be first reverted to a pluripotent state and then further differentiated 
into dopaminergic neurons. This allows investigation of the disease in vitro, in dopaminergic cells 
with the full genetic background of a PD individual. Such in vitro models may prove invaluable in 
the pursuit of disease-modifying therapies. However, future developments aside, we believe that 
the existing elementary observations from PD iPSC experiments already permit a deep, 
fundamental re-evaluation of the nature of the sporadic late-onset form of the disease. 
     We start by recalling the key observations in two of these PD iPSC studies. In both cases, skin 
fibroblasts from sporadic PD patients (presuppose sporadic henceforth) were reprogrammed back 
into pluripotent stem cells, which were then differentiated into dopaminergic neurons. Sánchez-
Danés et al. [15] reported that, by comparison with neurons identically derived from fibroblasts 
from healthy controls, neurons originating in fibroblasts from PD patients consistently showed 
alterations that could be associated with a PD phenotype. These included reduced numbers of 
neurites, more limited neurite arborizations and increases in caspase-3 activity, a marker for cell 
apoptosis. Woodard et al. [16] specifically utilized neurons derived from fibroblasts of two 
monozygotic twins discordant for PD. Vis-à-vis the neurons derived from the healthy twin 
fibroblasts, the neurons derived from the PD twin fibroblasts again showed multiple alterations 
that can be linked with a PD phenotype. These included lower dopamine levels, an elevated 
presence of alpha-synuclein in neurites, a delay in the emergence of spontaneous action 
potentials and an absence of synchronous neuronal activity. 
     Now, a well-established study by Tanner et al. [17] reported a mere 15.5% concordance of 
monozygotic twins in developing PD. An analogous study in Sweden by Wirdefeldt et al. [18] 
essentially confirmed this result, placing the concordance rate at 11%. In other words, excluding 
the monogenic cases, heredity does not ensure the emergence of PD. Therefore, the consistent, 
regular emergence of a PD phenotype in neurons derived from fibroblasts from PD patients cannot 
be attributed to a PD favorable germline genetic background in the patients. The conclusion is that 
the disease must have been present in the skin fibroblasts from the patients. PD is thus a cell-
generic state, not confined to neuronal cells. We propose to fundamentally define PD as a 
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characteristic pathological deviation in the expression program of a cell: the PD expression-state, 
or PD-state for short [19,20]. Reports of a characteristic PD gene-expression signature across 
multiple tissues directly support this view [20,21,22,23]. The recent observation of a unique, 
concordant pattern of methylation in post-mortem frontal cortex samples and peripheral blood 
leukocytes from PD patients [24] reinforces this standpoint, further indicating that the PD-state 
may be stabilized by DNA epigenetic modifications. Due to the cell processes it affects the most, 
the PD-state deviation would be particularly damaging in a neuronal context, ultimately leading to 
neuron death and the ensuing observed clinical signs. 
 
THE PD-STATE DOES NOT ARISE INDEPENDENTLY IN CELLS ACROSS THE ORGANISM 
     In spite of possessing a multitude of self-repair mechanisms, cells age [25]. At a primary level, 
they gradually accumulate dysfunctional molecules, as well as random mutations and other 
assorted alterations in their genetic code. Ultimately, at the phenotypic level this produces the 
external signs of aging  that we are all able to recognize. As a source of free radicals, mitochondria 
and the mitochondrial DNA are particularly vulnerable to oxidative stress damage [26]. This has led 
to the fundamental theory that mitochondrial dysfunction caused by oxidative stress plays a 
central role in aging [27,28]. With PD arising at old age and with mitochondrial function specifically 
known to be compromised in a variety of cell types in PD patients [29,30,31,32], the mitochondrial 
theory of aging broadly views PD as yet another manifestation of this phenomena [11]. 
     It is conceivable that accumulated random damage, perhaps in mitochondrial DNA and due to 
oxidative stress, eventually induces the gene expression program of a cell to shift to the PD-state. 
The shift to the PD-state in a cell could thus be viewed as a probabilistic event, its likelihood a 
(nonlinearly) increasing function of the built up damage associated with aging. 
     However, it is no longer plausible that cells throughout the organism acquire the PD-state 
independently, in the above fashion. To see this, consider two monozygotic twins, one diagnosed 
with PD long ago, the other so far not so, in spite of having by now a far greater amount of aging-
associated damage than his PD twin did at the time of diagnosis. This ordinary scenario [17] poses 
a paradox, in light of the huge differential in the number of cells that have shifted to the PD-state 
in each twin. The fact that at the time of clinical diagnosis over 50% of the dopaminergic neurons 
are believed to have already died [33] does not dispel the paradox. Thus, we must conclude that 
the PD-state cannot have arisen independently in each affected cell of a PD patient. A mechanism 
for the propagation of the PD-state must exist. 
     We make two additional remarks regarding the above argument. Firstly, the described 
stochastic process shifting one or a few cells to the PD-state in one twin but none in the other 
does not pose a paradox. Only the collective shifting of many more cells in one twin than the other 
is not tenable. Therefore, aging-associated damage, caused by oxidative stress in mitochondria, 
could still be the trigger for a primordial cell in the organism to shift to the PD-state. Secondly, 
aging-associated cellular damage may not be essential to the subsequent dissemination of the PD-
state across the organism since, as argued, this dissemination is occurring via a distinct 
propagation mechanism. 
     There are two more direct pieces of evidence supporting a propagation dynamic in PD. First, 
there are the post-mortem histo-pathological analyses of neuronal tissue from patients that 
passed away at different stages of the disease. These appear to support a chronological physical 
spread of Lewy-bodies across the nervous system [34]. Second, there are the surgical 
transplantations of fetal ventral mesencephalic dopaminergic neurons as a treatment of PD. A 
number of post-mortem analyses over 10 years after the transplant detected Lewy-bodies and 
Lewy neurites in grafted neurons, in spite of the neurons still young age [35,36]. This latter fact is 
in addition evidence of the non-essentiality of cellular aging to the propagation of the PD-state. 
PeerJ PrePrints | https://dx.doi.org/10.7287/peerj.preprints.1314v1 | CC-BY 4.0 Open Access | rec: 19 Aug 2015, publ: 19 Aug 2015
P
re
P
rin
ts
     In sum, in this section we have argued that aging-associated damage caused by oxidative stress 
in mitochondria could well be the trigger for an individual cell to shift its gene expression program 
to the PD-state. The shift to the PD-state would be a probabilistic event, its likelihood increasing 
nonlinearly with that accumulated damage in the cell. On the other hand, the subsequent 
appearance of large numbers of cells in the PD-state across the organism can no longer be 
explained by such a cell autonomous process. Rather, it must result from a separate mechanism of 
propagation of the PD-state. 
 
THE PROPAGATION OF THE PD-STATE 
     The spread of the PD-state is a rather slow process, as evidenced by the 10 or so years that it 
takes for an implanted fetal neuron in the brain of a PD patient to produce Lewy bodies [35,36]. 
The mechanism of propagation of the PD-state remains undetermined. However, new modes of 
inter-cellular communication continue to be discovered [37]. It is safe to say that we still 
underestimate the ways in which cells can communicate. Therefore, the fact that a mechanism for 
the transmission of the PD-state is not known at present, does not detract from the possibility of 
such said transmission. In this section, we discuss how propagation of the PD-state may take place. 
     A currently popular hypothesis is that alpha-synuclein can behave as a prion and PD is a prion 
disorder [6,10]. Under this theory, a misfolded form of alpha-synuclein would be self-propagating, 
having the ability to induce further misfolding in well-conformed alpha-synuclein. This process 
would underlie the spread of misfolded alpha-synuclein from cell to cell. However, a western blot 
analysis did not detect any alpha-synuclein in the fibroblasts utilized in the PD iPSC experiments 
discussed earlier [16]. Therefore, a PD phenotype in fibroblast-derived neurons cannot be 
explained by the lingering presence of a hypothetical infectious form of alpha-synuclein.       
     Nevertheless, the possibility that a different particular molecule (or higher-level entity) is 
responsible for transmitting the PD-state remains open. Recently, the intercellular exchange of 
mitochondrial DNA (mtDNA) has been demonstrated [38,39]. We suggest that such intercellular 
mtDNA transfers could enable propagation of the PD-state. 
     Comprehensive research with neuron-platelet cybrids supports that a particular mtDNA may 
suffice to set off the PD-state in a cell. A PD cybrid cell is created in vitro by the fusion of a 
neuronal cell depleted of endogenous mtDNA with an enucleated platelet from a PD donor. Thus, 
the mtDNA of the cybrid cell is that of the platelet from the PD patient, while its nuclear DNA is 
that of the disease-free neuronal cell. Various PD characteristic alterations have been observed in 
PD cybrids, most prominently, inclusions that replicate the essential biochemical and structural 
features found in Lewy-bodies in the brain of PD patients [12,40,41]. 
     The ability of mtDNA to both induce epigenetic modifications and modulate gene-expression in 
nuclear DNA supports the sufficiency of mtDNA to trigger the PD-state in a cell. In the context of 
tumorigenesis, work by Smiraglia et al. [42] and by Xie et al. [43] shows that alterations to mtDNA 
affect the methylation pattern of various nuclear genes. Bellizzi et al. [44] report that methylation 
and gene expression patterns of nuclear genes in cybrids depend on the mtDNA donor 
haplogroup. Kelly et al. [45] proposed that mtDNA haplotypes play a pivotal role in the process of 
differentiation and mediate the fate of the cell. In mouse undifferentiated and differentiating 
embryonic stem cells, with the same nuclear DNA haplotype but distinct mtDNA haplotypes, they 
observed mtDNA haplotype-specific expression of genes involved in pluripotency, differentiation, 
mitochondrial energy metabolism, and DNA methylation. 
     No specific mutations in mtDNA have been consistently associated with PD [46]. However, it 
will be worth exploring whether the PD-state is stabilized in mitochondria by characteristic mtDNA 
epigenetic modifications. Methylation of mtDNA was reported decades ago [47,48,49], but it was 
since then mostly ignored. Fortunately, there has been a recent renewed interest in this possibility 
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and its implications, that started with the report by Shock et al. [50] that DNA methyltransferase 1 
translocates to mitochondria and that 5-hydroxymethylcytosine and 5-methylcytosine are present 
in mtDNA. 
     Finally, an mtDNA propagating the PD-state would have to possess a differential intra-cellular 
replication ability in order for its intra-cellular frequency to reach functionally significant levels. 
This is certainly possible, as evidenced by cells containing mutated mtDNA being often 
homoplasmic, which indicates a preferential accumulation of a specific mutated mtDNA variant 
[51,52].  
     As an alternative to the above suggested mitochondrial based transmission, propagation of the 
PD-state could result from a complex interplay between multiple inter-cellular signals and the 
cell's expression-state [53]. In biology there is traditionally an emphasis on identifying pathways 
and signaling cascades that permit explaining events in a linear, mechanistic fashion. But in reality, 
living organisms were fashioned by evolution rather than by intelligent design. Therefore 
mechanistic descriptions, although reassuring, may not always add much predictive value. With 
many biological processes, it may be better to aim for a phenomenological understanding that 
allows prediction and hopefully modulation of the relevant dynamics. The propagation dynamics 
of the PD-state could be one such case. 
 
A SITE OF ORIGIN FOR THE PD-STATE 
     The previous section was concerned with the spread of the PD-state. Now, propagation implies 
the existence of an origin. We have mentioned that aging-associated damage caused by oxidative 
stress in mitochondria could be the trigger for a primordial cell, or few cells, to shift their gene 
expression program to the PD-state. A relevant question is where, if anywhere in particular, would 
a primordial PD-state cell most commonly arise. In this section, we suggest the hematopoietic 
stem cell niche as a site to consider. 
     First recall that gene expression [20,22], DNA methylation [24], neuron-platelet cybrid 
[41,40,12] and bioenergetic [29] analyses, all support the presence of the PD-state in circulating 
hematopoietic cells. Given the short lifespan of blood cells (days for platelets [54] and 
granulocytes [55] and weeks for lymphocytes, with the exception of memory cells [56]) vis-à-vis 
the decade long timescale for the transmission of PD across the neuronal system [34,35,36], the 
above signs of  PD in blood point to circulating hematopoietic cells acquiring the PD-state at 
hematopoiesis, rather than after maturation. 
     Hematopoiesis is altered with aging. Research in the topic relies heavily on work with mice. The 
evidence alluded to henceforth in this section is all based on mouse models, except where noted 
otherwise. In terms of global gene expression in hematopoietic stem cells (HSCs), nitric oxide 
mediated signal transduction, the NF-kB cascade and the pro-inflammatory response are the most 
age up-regulated processes, while chromatin silencing, single-strand break repair, SMAD protein 
nuclear translocation and chromatin remodeling are the most down-regulated ones [57]. 
Alterations at the HSC epigenetic level are supported by many chromosomal regions showing a 
coordinated change in transcriptional activity [57]. Fate-wise a skewing to the myeloid line and a 
diminished lymphoid potential are observed with aging [58]. 
     It has been known for long that reactive oxygen species (ROS), if not properly checked, have the 
potential to cause indiscriminate cellular damage [27]. However, today ROS are also appreciated 
to play a functional  signaling role in activating processes such as the inflammatory and stress 
responses [25,59]. There is additionally indication of a specific ROS role in regulating 
hematopoiesis [60]. In particular, evidence associates abnormal ROS levels at old age with a 
dysfunction in both the proliferation and the differentiation dynamics of HSCs. We briefly highlight 
some of this evidence. In vitro work has shown that exposure to H2O2 can lead to chromosomal 
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translocations in HSCs [61]. Ionizing radiation is also known to affect HSCs, namely it has been 
found to promote differentiation, short-term apoptosis and long-term senescence of HSCs [62]. In 
vivo work with Drosophila supports the role of ROS in the regulation of hematopoietic cell fate. 
Increasing ROS beyond its basal level in Drosophila multipotent hematopoietic progenitors triggers 
their precocious differentiation [63]. Conversely, scavenging ROS from these hematopoietic 
progenitors retards their differentiation into mature blood cells [63]. It is well-established that 
serial transplantation of human HSCs into immunodeficient mice leads to both elevated 
intracellular ROS levels and to premature HSC senescence [64,65,66]. Yahata et al. [64] and Ito et 
al. [66] independently reported that antioxidant pharmacological inhibition of ROS can mitigate 
this deteriorating HSC phenotype. Caloric restriction in BalbC mice was similarly shown to 
postpone HSC senescence [65]. Finally, the same protective effect was achieved by SIRT3 up-
regulation in HSCs [67]. HSCs are highly-enriched in this mammalian sirtuin, except for its 
suppression at old age [67]. SIRT3 regulates the global acetylation landscape of mitochondrial 
proteins and reduces oxidative stress [67]. Mechanistically, the FoxO transcription factors [68] and 
the p53 [69], Akt [70], MAPK [66] and ATM [71] pathways have all been implicated in the ROS 
modulation of hematopoiesis. 
     At the genetic level, some emerging evidence may also turn out to connect PD and the 
hematopoietic system, although its interpretation is not yet completely clear. A new study by Xiao 
et al. [72] found hematologic abnormalities in alpha-synuclein knock-out mice indicative of an 
heretofore unknown role of this molecule in late-stage hematopoiesis. A genome-wide association 
study found a rare non-synonymous mutation in DZIP1 as a risk factor for PD [73]. DZIP1 is a 
component of the Hedgehog signaling pathway [74]. Besides its role in directing embryonic 
pattern formation, the hedgehog pathway has been implicated in the maintenance of adult stem 
cell niches, including both neuronal [75] and hematopoietic stem-cells [76]. Finally, PD patients are 
over five times more likely to be carriers of the mutated form of GBA responsible for the Gaucher's 
autosomal recessive disease [77]. Gaucher's disease is characterized by low blood platelets levels, 
anemia, and the accumulation of the glycolipid glucocerebroside in the mononuclear phagocyte 
system [78]. 
     In summary: i) a large body of evidence points to PD patients consistently having circulating 
hematopoietic cells in the PD-state; and ii) we have argued why their PD-state may be acquired at 
hematopoiesis rather than after maturation, from the disruption in ROS homeostasis that arises 
with age in the hematopoietic stem-cell niche. 
 
CONCLUSION 
     Hypotheses, even if eventually proved incorrect, can elicit valuable directions for experimental 
research efforts. Calling upon some recent findings that we considered relevant to the PD field, as 
well as on various established lines of PD research, we presented a comprehensive theory on the 
nature, origin and inter-cellular mode of propagation of late-onset sporadic Parkinson's disease. 
We now review this hypothesis and interpret a few additional observations in its light.  
     We propose to define PD as a characteristic pathological deviation in the global gene expression 
program of a cell: the PD expression-state, or PD-state for short. Most significantly, any cell could 
be in the PD-state, it would be a universal cell state. However, due to the cell processes it affects 
the most, the PD-state deviation would be particularly damaging in a neuronal context, ultimately 
leading to neuron death and the ensuing observed clinical signs of PD. 
     Aging-associated damage caused by oxidative stress in mitochondria could be the trigger for a 
primordial cell to shift to the PD-state. In particular, hematopoietic cells could be the first to 
acquire the PD-state, at hematopoiesis, as a result of the disruption in ROS homeostasis that arises 
with age in the hematopoietic stem-cell niche. The appearance of the PD-state deviation at 
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hematopoiesis would be a lifetime relatively unlikely, mostly probabilistic event, its odds not 
greatly affected by genetics or lifelong environmental exposures. The observed low statistical 
correlation of PD incidence with genetic and environmental factors would follow from this PD-
state initiation dynamics. 
     Propagation of the PD-state across the organism would occur in a second phase and via a 
distinct mechanism. We suggested that mtDNA, with its ability to move across cells and to 
modulate the cellular global gene expression state, could form the basis for the intercellular 
propagation of the PD-state. The mtDNA-based PD propagation dynamics would occur on a time-
scale of years, as observed in patients, and not be aging-dependent, in contrast with the PD-state 
initiation dynamics. 
     Under physiological conditions, mice are not susceptible to PD late in life, in spite of clearly 
showing an aging phenotype just as humans do [79]. As per our hypothesis, the aging-dependent 
PD initiation dynamics should occur in aged mice, just as well. The absence of a PD phenotype in 
mice would thus follow instead from the non-aging dependent mtDNA-based spread dynamics of 
PD. This propagation dynamics would be too slow relative to the lifetime of a mouse, for the 
condition to affect the neuronal system. 
     Two of the early symptoms of PD in humans are an impaired sense of smell [7] and 
gastrointestinal dysfunction [80]. Both have been reported as much as 10 years before the 
appearance of symptoms at the motor level. They are typically interpreted as supporting the role 
of an invading external agent - via the olfactory or gastro-intestinal entry points - in inducting PD 
[9]. However, another characteristic shared by the olfactory bulb and the gastro-intestinal tract is 
that they are both sites of very active stem-cell based tissue regeneration [81,82]. The rapid cell 
renewal and the plasticity of immature cells could facilitate both the cellular uptake of carriers of 
external mtDNA and the global cellular reprogramming to the PD-state, explaining the olfactory 
bulb and the gastro-intestinal tract being some of the earlier sites to which the PD-state would 
spread. 
     Finally, we note that although our hypothesis was presented in the context of PD, it is apparent 
that, if correct, an analogous, parallel etiology may be applicable to Alzheimer's disease. 
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